Literature DB >> 20978577

Damage control: cavoatrial anastomosis during a catastrophic right intrapericardial pneumonectomy.

Timothy L Van Natta1, Kalpaj R Parekh, Daniel T Dearmond, Mark D Iannettoni.   

Abstract

While undergoing an intrapericardial pneumonectomy for a massive right pulmonary inflammatory pseudotumor that had invaded the mediastinum, an 18-year-old woman experienced a nearly fatal iatrogenic complication. Dense scarring adjacent to the pseudotumor had drawn in the superior vena cava posterolaterally and fused the right main pulmonary artery to the right superior pulmonary vein within the pericardium. The failure of a linear stapler to secure the pulmonary vessels led to torrential hemorrhage. Attempts to control the bleeding resulted in inadvertent superior vena cava occlusion and central venous pressure elevation. Because cardiopulmonary bypass might not have been reliably established in time to avoid irreversible cerebral ischemia, we borrowed a technique from congenital heart surgery and rapidly fashioned a cavoatrial connection. The patient survived the operation without negative neurologic or cardiac sequelae, recovered fully, and had no recurrence of the pseudotumor. Herein, we describe the intraoperative decisions that were made under intense time pressure to avert catastrophe.

Entities:  

Keywords:  Catastrophic illness; cerebrovascular circulation; iatrogenic disease; intraoperative period; lung neoplasms/surgery; pneumonectomy/adverse effects; pulmonary artery/pathology; time factors; treatment outcome; vena cava, superior/surgery

Mesh:

Year:  2010        PMID: 20978577      PMCID: PMC2953238     

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN: 0730-2347


  8 in total

1.  The surgical treatment of partial and total anomalous pulmonary venous connections.

Authors:  J L EHRENHAFT; E O THEILEN; M S LAWRENCE
Journal:  Ann Surg       Date:  1958-08       Impact factor: 12.969

2.  Extended pulmonary resections of advanced thoracic malignancies with support of cardiopulmonary bypass.

Authors:  Karsten Wiebe; Hassina Baraki; Paolo Macchiarini; Axel Haverich
Journal:  Eur J Cardiothorac Surg       Date:  2005-12-20       Impact factor: 4.191

3.  Inflammatory pseudotumor of the lung in adults.

Authors:  Giulio Melloni; Angelo Carretta; Paola Ciriaco; Gianluigi Arrigoni; Stefano Fieschi; Nathalie Rizzo; Edgardo Bonacina; Giuseppe Augello; Pier Angelo Belloni; Piero Zannini
Journal:  Ann Thorac Surg       Date:  2005-02       Impact factor: 4.330

4.  Operative strategies for resection of pulmonary sarcomas extending into the left atrium.

Authors:  R J Korst; T K Rosengart
Journal:  Ann Thorac Surg       Date:  1999-04       Impact factor: 4.330

5.  Inflammatory pseudotumors of the lung.

Authors:  R J Cerfolio; M S Allen; A G Nascimento; C Deschamps; V F Trastek; D L Miller; P C Pairolero
Journal:  Ann Thorac Surg       Date:  1999-04       Impact factor: 4.330

6.  Resection of locally advanced (T4) non-small cell lung cancer with cardiopulmonary bypass.

Authors:  Marc de Perrot; Elie Fadel; Sacha Mussot; Angela de Palma; Alain Chapelier; Philippe Dartevelle
Journal:  Ann Thorac Surg       Date:  2005-05       Impact factor: 4.330

7.  Complete resection of pulmonary inflammatory pseudotumors has excellent long-term prognosis.

Authors:  Dominique Fabre; Elie Fadel; Sunil Singhal; Vincent de Montpreville; Sacha Mussot; Olaf Mercier; Olivier Chataigner; Philippe G Dartevelle
Journal:  J Thorac Cardiovasc Surg       Date:  2008-09-19       Impact factor: 5.209

8.  An alternative method for repair of partial anomalous pulmonary venous connection to the superior vena cava.

Authors:  H E Warden; R A Gustafson; T J Tarnay; W A Neal
Journal:  Ann Thorac Surg       Date:  1984-12       Impact factor: 4.330

  8 in total
  1 in total

Review 1.  [Intraoperative bleeding during thoracic surgery : avoidance strategies and surgical treatment concepts].

Authors:  M Schirren; S Sponholz; S Oguhzan; N Kudelin; C Ruf; S Trainer; J Schirren
Journal:  Chirurg       Date:  2015-05       Impact factor: 0.955

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.